Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00015
|
|||||
| Drug Name |
Adefovir
|
|||||
| Synonyms |
((2-(6-Amino-9H-purin-9-yl)ethoxy)methyl)phosphonic acid; 2-(6-aminopurin-9-yl)ethoxymethylphosphonic acid; 9-(2-(Phosphonomethoxy)ethyl)adenine; 9-(2-Phosphonylmethoxyethyl)adenine; ADEFOVIR; GS 0393; GS 393; GS-0393; N-(2-Phophonomethoxyethyl-2,6-diaminopurine); N-(2-Phosphonylmethoxyethyl)adenine; PMEA; {[2-(6-Amino-9h-Purin-9-Yl)ethoxy]methyl}phosphonic Acid
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Hepatitis B virus infection [ICD11: 1E51.0, 1E50.1] | Approved | [1] | |||
| Herpes simplex virus infection [ICD11: 1F00] | Approved | [1] | ||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C8H12N5O4P
|
|||||
| Canonical SMILES |
C1=NC(=C2C(=N1)N(C=N2)CCOCP(=O)(O)O)N
|
|||||
| InChI |
InChI=1S/C8H12N5O4P/c9-7-6-8(11-3-10-7)13(4-12-6)1-2-17-5-18(14,15)16/h3-4H,1-2,5H2,(H2,9,10,11)(H2,14,15,16)
|
|||||
| InChIKey |
SUPKOOSCJHTBAH-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 106941-25-7
|
|||||
| Pharmaceutical Properties | Molecular Weight | 273.19 | Topological Polar Surface Area | 136 | ||
| Heavy Atom Count | 18 | Rotatable Bond Count | 5 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 8 | |||
| XLogP |
-2
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:2469
|
|||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| MRP1 | Transporter Info | Multidrug resistance-associated protein 1 | Substrate | [3] | ||
| MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [4] | ||
| MRP4 | Transporter Info | Multidrug resistance-associated protein 4 | Substrate | [5] | ||
| OAT1 | Transporter Info | Organic anion transporter 1 | Substrate | [6] | ||
| OAT3 | Transporter Info | Organic anion transporter 3 | Substrate | [7] | ||
| Drug-Transporter Activity Data | ||||||
| Drug-Transporter Activity Data | OAT1 | Transporter Info | Km = 23.8 microM | Chinese hamster ovary (CHO) cells-OAT1 | [6] | |
| OAT1 | Transporter Info | Km = 30 microM | Oocytes-OAT1 | [8] | ||
| OAT3 | Transporter Info | Km = 1220 microM | BHK-21 cells-OAT3 | [9] | ||
| References | ||||||
| 1 | Adefovir was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | ABC transporters and their role in nucleoside and nucleotide drug resistance. Biochem Pharmacol. 2012 Apr 15;83(8):1073-83. | |||||
| 3 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
| 4 | Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol. 2010 Feb;44(2):152-67. | |||||
| 5 | Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol. 2007 Feb;71(2):619-27. | |||||
| 6 | Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol. 2000 Mar;11(3):383-93. | |||||
| 7 | FDA Drug Development and Drug Interactions | |||||
| 8 | The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol Pharmacol. 1999 Sep;56(3):570-80. | |||||
| 9 | Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation. Antimicrob Agents Chemother. 2009 Jan;53(1):150-6. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.